Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Accumulated Expenses (2021 - 2025)

PAVmed (PAVM) has 5 years of Accumulated Expenses data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, changed N/A, while the annual FY2024 figure was $5.2 million, 21.88% down from the prior year.
  • Accumulated Expenses reached $2.7 million in Q3 2025 per PAVM's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.8 million in Q2 2024 and bottomed at $1.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $3.7 million, with a median of $3.5 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 208.74% in 2022, then plummeted 65.69% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $4.3 million in 2021, then dropped by 13.01% to $3.7 million in 2022, then skyrocketed by 78.84% to $6.6 million in 2023, then dropped by 21.88% to $5.2 million in 2024, then tumbled by 48.61% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.7 million in Q3 2025, $2.8 million in Q2 2025, and $2.3 million in Q1 2025.